Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An, Phase Ib/II Clinical Trial to Evaluate the Safety and Efficacy of SYHA1813 Single Agent or in Combination With Different Regimens in Unresectable Locally Advanced or Metastatic Solid Tumors.

NCT06682611 is registered in ClinicalTrials.gov with Shanghai Runshi Pharmaceutical Technology Co., Ltd as lead sponsor.

NCT NCT06682611
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06682611 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An, Phase Ib/II Clinical Trial to Evaluate the Safety and Efficacy of SYHA1813 Single Agent or in Combination With Different Regimens in Unresectable Locally Advanced or Metastatic Solid Tumors.
Lead sponsor
Shanghai Runshi Pharmaceutical Technology Co., Ltd
Phase
Phase 1/2
Overall status
Not yet recruiting
Start date
November 13, 2024
Completion date
November 13, 2027
Enrollment
380 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

unresectable locally advanced or metastatic solid tumors